Andrea obtained her MD at the University of Munich. After her post-doc at the University of Bonn, she joined EPFL as an assistant professor in 2014, where she became Full Professor in 2021. Her research focuses on mechanisms of innate immunity. She played a major role in deciphering how cells respond to intracellular DNA as a signal of infection via the so-called cGAS-STING pathway - a fundamental discovery, which paved the way for promising new immunotherapies. Amongst several distinctions, Andrea Ablasser is recipient of the EMBO Gold Medal, the Dr. Josef Steiner Cancer Award, the Coley Award, the Sanofi-Institut Pasteur Award, the National Latsis Prize, the ACTERIA Prize, and the Eppendorf Award, and she is an elected member of EMBO and Leopoldina. She has been nominated "Highly Cited Researcher". She is the founding scientist of IFM Due, a biopharmaceutical company developing cGAS-STING antagonists for the treatment of inflammatory disorders.

Harold Alan Pincus, MD, is a professor and vice chair of the Department of Psychiatry and co-director of the Irving Institute for Clinical and Translational Research at Columbia University and the New York State Psychiatric Institute. Dr. Pincus also serves as a senior scientist at the RAND Corporation. Previously, he was director of the RAND-University of Pittsburgh Health Institute and executive vice chair of the Department of Psychiatry at the University of Pittsburgh. He is the national director of the Health and Aging Policy Fellowship (supported by the John A. Hartford Foundation, West Health Policy Institute and Atlantic Philanthropies) and previously directed national programs for the Robert Wood Johnson and MacArthur Foundations. Earlier, Dr. Pincus was deputy medical director of the American Psychiatric Association (APA) and founding director of APA's Office of Research, was the special assistant to the director of the National Institute of Mental Health (NIMH) and served on White House and congressional staffs as a Robert Wood Johnson Foundation Clinical Scholar. Dr. Pincus has been appointed to the editorial boards of 12 scientific journals and published more than 500 scientific publications in health services research, science policy, research career development, quality of care and the diagnosis, classification and treatment of mental disorders. He has led research and research training programs totaling over $250 Million in external funding. Among multiple other national/international committee appointments, he is co-chair of the National Quality Forum Standing Committee on Behavioral Health and the World Health Organization's ICD-11 Committee on Quality and Patient Safety and was vice chair of the Task Force on DSM-IV. Dr. Pincus was named 2019 Mentor of the Year at the Columbia University Medical Center and the 2017 recipient of the C. Charles Burlingame Award by the Institute of Living for contributions to the field of psychiatry and has received the William C. Menninger Memorial Award of the American College of Physicians for distinguished contributions to the science of mental health, the Research Mentorship Award from the American Association of Chairs of Departments of Psychiatry and APA for contributions to the career development of young investigators, Vestermark Award from the National Institute of Mental Health and APA for contributions to psychiatric education, Health Services Research Senior Scholar Award of the APA and Columbia University's Emily Mumford Medal among other honors. For 22 years he worked one evening a week at a public mental health clinic caring for patients with severe mental illnesses.

Dr. Andreasson is Professor in the Department of Neurology and Neurological Sciences, and is a neurologist who treats patients with dementia and is also engaged in basic research in neurodegenerative disorders. Dr. Andreasson received her M.D. degree at Columbia University College of Physicians & Surgeons, and completed her residency in Neurology at Johns Hopkins School of Medicine.
She carried out her postdoctoral training in the Johns Hopkins Department of Neuroscience, where she began her research studies on the function of brain inflammation in development of neurodegenerative disease. The objectives of her laboratory research are to identify specific inflammatory pathways that may be targeted to prevent and treat neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease.

Dr Antebi received his PhD from Massachusetts Institute of Technology, and performed his post-doctoral research at the Johns Hopkins University. He first worked as an Independent Group Leader at the Max Planck Institute for Molecular Genetics, Berlin, and then as an Associate Professor at Baylor College of Medicine, Houston.In 2008, he became a founding Director of the Max Planck Institute for Biology of Ageing, Cologne. His research has focused on unravelling regulatory mechanisms governing animal longevity, and has discovered that hormone driven developmental clocks regulate life span and that small nucleoli are a conserved cellular hallmark of longevity.

Dr. Nir Barzilai is the founding director of the Institute for Aging Research, the Nathan Shock Center of Excellence in the Basic Biology of Aging and the Paul F. Glenn Center for the Biology of Human Aging Research at Albert Einstein College of Medicine of Yeshiva University (Einstein). He also directs the Longevity Genes Project, a genetics study of over 600 families of centenarians and their children. The participants are all Ashkenazi Jews, a group selected for their genetic homogeneity, which makes it easier to identify significant genetic variations. Dr. Barzilai found that many of the centenarians had very high levels of HDL, or the "good cholesterol." Dr. Barzilai is also co-founder of CohBar, Inc., a biotechnology company developing mitochondria based therapeutics to treat diseases associated with aging.

Dr. Barzilai discovered several "longevity genes" in humans that were validated by others. These include variants in genes involved in cholesterol metabolism (CETP and APOC3), metabolism (ADIPOQ and TSHR) and growth (IGF1R). These genes appear to protect centenarians against major age-related diseases, such as cardiovascular disease, cancer, type 2 diabetes and dementia.

Joseph Baur earned his Ph.D. from the University of Texas Southwestern Medical Center in Dallas, Texas, where he studied mechanisms that limit the lifespan of cultured human cells under Drs. Jerry Shay and Woody Wright. He then moved to Harvard Medical School where he trained as a postdoctoral fellow with Dr. David Sinclair. There he developed a strong interest in the regulation of aging and metabolism by sirtuins, a conserved class of enzymes that require nicotinamide adenine dinucleotide (NAD) as a co-substrate. His lab currently studies metabolic and signaling pathways by which nutrient intake can influence longevity, with a particular emphasis on NAD and mTOR.

Joe Betts-LaCroix began his distinguished entrepreneurial career as a scientist at Harvard, MIT, and Caltech. As part of a three-person team at Caltech, he contributed to the discovery of factors governing electron-tunneling rates in proteins. Their work has been published in journals such as Science and JACS, accumulating over 1500 citations.

He has co-founded three venture-funded startups. His first, OQO, created the world's smallest Windows computer (Guinness World Record 2006) and was acquired by Google. His second, Vium, automated animal research to accelerate medical studies and was acquired by Recursion Pharma. He has also spent several years as a part-time partner at Y Combinator, mentoring and investing in numerous bio startups.

Currently, Betts-LaCroix serves as CEO of his third [venture-funded] startup, Retro Biosciences. The company’s mission is to increase healthy human lifespan by ten years.

Specialist in Internal Medicine, Artificial Intelligence (AI) and digital health, with extensive experience in scientific research and clinical practice at the following well known and highly reputable institutions. Research focus is oncology and longevity medicine, Artificial Intelligence (AI) and digital health, precision medicine, biogerontology, and geronto-oncology. EB published over 100 peer-reviewed papers, is a frequent speaker at scientific and medical conferences in Asia and Europe. Long term member of various medical societies, e.g. European Federation of Internal Medicine, World Academy of Medical Sciences, Swiss Society of Internal Medicine etc.

EB spent a decade practicing medicine, lecturing at medical schools and performing clinical and translational research in New York, Shanghai and Basel, with extensive experience in scientific research and clinical practice at the following well-known and highly reputable institutions: University Hospital of Basel, Fudan Cancer Institute and Hospital; Zhongshan Hospital, Renji Hospital and Shanghai East Hospital. EB sits on several scientific and advisory boards of biotech and longevity hubs. Currently also affiliated with the Centre of Healthy Aging, Universität Zürich, and prev. senior attending physician of internal medicine at the University Hospital Basel.

Swiss board certified as internal medicine specialist (FMH), trained in Europe, USA and China (Harvard Medical School affiliated hospitals (Mass General Hospital, Beth Israel MD, Dana Farber Institute) and Columbia University NYC; Tongji University hospitals, Shanghai and University Hospitals of Zurich and Basel (Switzerland).

Dr. Gil Blander is internationally recognized for his research in the basic biology of aging and translating research discoveries into new ways of detecting and preventing age-related conditions. He leads a team of biology, nutrition & exercise physiology experts, and data scientists at InsideTracker, and has been featured in CNN Money, The New York Times, Forbes, Financial Times, The Boston Globe to name a few.
Dr. Gil Blander received a Ph.D. in biology from the Weizmann Institute of Science and completed his Post Doctoral fellowship at MIT, before going on to found InsideTracker. InsideTracker was founded in 2009 by top scientists from acclaimed universities in the fields of aging, genetics, and biology, InsideTracker is a truly personalized nutrition and performance system. Our mission is to help people add years to their lives and life to their years by optimizing their bodies from the inside out. By analyzing your body's data, we can give you a crystal clear picture of what's going on inside you along with a science-backed action plan for improving your health and becoming your best self.

Dr. Sarah Bonnes is an associate professor of medicine at the Mayo Clinic, Rochester Minnesota. She is board certified in Internal Medicine, as well as a diplomat of the American College of lifestyle medicine, and physician nutrition specialist. With this unique intersection of clinical expertise, she has been asked to help develop their healthy longevity Clinic and research practice. She sees patients in the General Internal Medicine Consultative Medicine practice, intestinal failure Clinic, and healthy longevity Clinic.
In addition to her clinical interest and expertise, Dr. Bonnes remains a committed educator. She serves as vice chair of Education for the division of General Internal Medicine, and as an associate program director for their internal medicine residency.

Dr. Brunet obtained her B.Sc. from the Ecole Normale Supérieure in Paris and her Ph.D. from the University of Nice, France. She did her postdoctoral training with Dr. Michael Greenberg at Harvard Medical School. Dr. Brunet is interested in the molecular mechanisms of aging and longevity. She wants to understand the mechanism of neural stem cell aging. She also seeks to discover novel genes regulating longevity, notably developing a new short-lived vertebrate, the African killifish. Dr. Brunet has published over 80 peer-reviewed papers and reviews. She has received several awards, including the Pfizer/AFAR Innovation in Aging Research Award and the Vincent Cristofalo "Rising Star" Award in Aging Research. She received a Pioneer Award and a Transformative Award from the NIH Director's fund, which supports scientists who propose pioneering and transforming approaches to major challenges in biomedical research.

Dr. Büttner is Associate Professor at Stockholm University. She studied biochemistry at the University of Tübingen, Germany, and received her PhD in molecular biology from the University of Graz, Austria, where she studied cell death pathways with Dr. Frank Madeo. Her research focuses on intracellular communication during cellular aging. The Büttner lab uses simple model systems to understand how organelle connectivity contributes to the maintenance of proteostasis and cellular fitness upon stress and during aging. Her research on cellular aging was awarded with the Austrian Josef Krainer-Würdigungspreis and the Hagberg Prize from the Royal Swedish Academy of Sciences.

Dr. de Cabo earned his Ph.D. in 2000 from the Department of Foods and Nutrition at Purdue University. He received a postdoctoral position in the Laboratory of Neurosciences at the National Institute on Aging in Baltimore, Maryland. In 2004, he was appointed as a tenure track investigator in the Laboratory of Experimental Gerontology. He is now a senior investigator and Chief of the Translational Gerontology Branch at NIA. His research has focused on the effects of nutritional interventions on basic mechanisms of aging and age-related diseases, the effects of caloric restriction on aging, and pharmacological interventions for healthy aging. Ultimately his research aims to identify interventions that will improve healthspan and lifespan with translational potential to benefit human aging.

Danica Chen is a Professor of Metabolic Biology, Nutritional Sciences & Toxicology at University of California at Berkeley and a member of Berkeley Stem Cell Center. She was a Searle Scholar, an Ellison Scholar, a Kavli Fellow, and a Hellman Fellow. Dr. Chen received Ph.D. in molecular and cell biology from University of California at Berkeley and obtained postdoctoral training in biology at Massachusetts Institute of Technology. Her research aims to understand the molecular and cellular mechanisms underlying aging-associated conditions and diseases and elucidate which aspects of aging-associated conditions are reversible. Recent studies from her lab have revealed mitochondrial stress as a cause of stem cell exhaustion and tissue degeneration during aging. She identified mitochondrial stress resistance programs that become dysregulated in aged stem cells, and demonstrated these programs can be targeted to improve survival and regenerative capacity of aged stem cells. These findings give hope for targeting aging-associated dysregulated cellular protective programs to reverse stem cell aging, tissue degeneration and dysfunction.

Dr. Xiaowei Chen is the founder of TeloSpring Health Technologies, Ltd. and TeloYounger Health Technologies, which provide tests for BioAge, as well as
anti-aging products and services.

Xiaowei holds a PhD in Biochemistry and Molecular Genetics from the University
of Pittsburgh, and was a postdoctoral fellow in Human Genetics at UCSF.
She attended Gifted Youth Class and department of Biology at University of Science and Technology of China for undergraduate studies.

In 2008, Xiaowei was elected as a Young Global Leader by the World Economic Forum.

Xiaowei is a serial entrepreneur. In 2014, Xiaowei founded Intertain, providing interactive entertainment for users on multi screens, including TV, mobile, tablet
and laptops. Intertain won top 10 prize of Global Entrepreneurship Contest among 3,000 contestants in 2015.

Prior to starting up her own businesses, Xiaowei was Chief Executive Officer for Telstra China. She was responsible for Telstra’s highly successful portfolio assets
in China, including Autohome (listed on NYSE in January, 2014).

Prior to joining Telstra, Xiaowei was CEO for Orange Sky Golden Harvest Entertainment Group, an integrated entertainment company including film production, cinema construction and operations, artistic management, advertising and new media.

Prior to Golden Harvest, Xiaowei was President for The9 Limited, an online games
company (Nasdaq: NCTY), and President of China.com, China’s first internet company listed overseas (HKEx: 8006), before The9 Limited. Prior to returning
to China in 2005, Xiaowei was consultant with McKinsey & Co, a global management consulting firm based in New York.

Xiaowei was Anchor and Executive Producer for China Central Television
from 1997 - 2001.

Christoph Correll, MD, is professor of psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and a medical director of the Recognition and Prevention (RAP) program at Zucker Hillside Hospital. He also currently serves as professor and chair of the Department of Child and Adolescent Psychiatry at Charité University Medicine in Berlin, Germany. He completed his medical studies at the Free University of Berlin in Germany and Dundee University Medical School in Scotland. He is board certified in general psychiatry and child and adolescent psychiatry, having completed both residencies at Zucker Hillside Hospital in New York City. Since 1997, he has been conducting research in New York, and in 2017, began working in Germany again.
Professor Correll has authored and co-authored more than 700 journal articles. He has served on several expert consensus panels on the use of antipsychotics across a range of psychiatric disorders, is a reviewer for more than 70 peer-reviewed journals and an editorial board member of 12 scientific journals. Professor Correll is the Principal Investigator or Steering Committee member of several large, federally funded grants. He has received more than 30 national and international research awards and fellowships for his work. Since 2014, the year of inception of this metric, he has been listed each year by Thomson Reuters/Clarivate/Web of Science as one of “The most influential scientific minds” and “Top 1% cited scientists in the area of psychiatry.”

Dr. Chini is a native from Brazil and has been at the Mayo Clinic for 30 years. Dr. Chini is a physician scientist. Dr. Chini received his MD, PhD from UFRJ in Brazil, and his anesthesiology residency was completed at the Mayo Clinic. Dr. Chini's research focus is in the fields of metabolism, nutrition, obesity, pharmacology, cancer and aging, and kidney disease. In particular, Dr. Chini is interested in nicotinamide adenine dinucleotide (NAD) metabolism and functions. He and his colleagues are exploring the nonoxidative and oxidative roles of NAD (as a signaling molecule and energy coin in cells). Dr. Chini's laboratory has done seminal work on NAD catabolism, including the description of the main enzyme responsible for the degradation of this molecule in mammalian tissues. This enzyme in named CD38 and is responsible for age-related NAD decline. Dr. Chini received several awards during his career.

Stefanie Dimmeler is born on 18.07.1967 in Ravensburg, Germany. Dr. Dimmeler received her undergraduate, graduate, and Ph.D. degree from the University of Konstanz in Konstanz (Germany) and then completed a fellowship in Experimental Surgery at the University of Cologne and in Molecular Cardiology at the University of Frankfurt (Germany). She is Professor of Experimental Medicine (since 2001) and Director of the Institute of Cardiovascular Regeneration, Center for Molecular Medicine at the University of Frankfurt since 2008. In the last years, she has been invited as a speaker in more than 300 national and international meetings and seminars and has presented various keynote lectures. She also received several awards. She is also spokesperson of the "Cardiopulmonary Institute" (CPI) which is funded by the Excellence Strategy Program of the German Research Foundation and spokesperson of the German Center for Cardiovascular Research (DZHK). She also received three Advanced Investigator Grants by the European Research Community (ERC). Her group elucidates the basic mechanisms underlying cardiovascular disease and vessel growth with the aim to develop new cellular and pharmacological therapies for improving the treatment of cardiovascular disease. Ongoing research focuses on epigenetic mechanisms that control cardiovascular repair, specifically non-coding RNAs.

Dr. Varun Dwaraka is the Head of Bioinformatics at TruDiagnostic, and an aging and longevity investigator specializing in epigenetics and bioinformatics. He received his BS from University of California, Santa Cruz and a PhD from the University of Kentucky. Dr. Dwaraka has used NGS and array technologies to identify key genes implicated in initiating salamander limb regeneration, and using multi-omic approaches to identify their upstream epigenetic targets. He has authored numerous publications relating to genetics, epigenetic clocks, DNA methylation, and tissue regeneration. He leads the development of epigenetic and multi-omic based clocks at TruDiagnostic Inc., a company focusing on methylation array-based diagnostics to empower clinicians and researchers in better understanding the fluid epigenome.

Dr. Dwaraka is a full member of the Sigma Xi, The Scientific Research Honor Society, and currently serves as a 2023 Foresight Fellow in Biotechnology and Health Expansion, awarded by the Foresight Institute. Dr. Dwaraka is passionate about implementing machine learning methods to advance predictive medicine, identify novel biomarkers, and create algorithms to better understand the biology of aging.

Dr Ewald has a longstanding interest in the molecular biology of healthy aging and age-related pathologies. His curiosity for aging research was ignited by the finding that neurons could regulate aging in model organisms and the finding that meditation could change the expression of stress-associated genes in humans. Fascinated by neurons and the mind, he went to New York to pursue a PhD in Neuroscience with Chris Li working on Alzheimer's Disease (AD) related proteins in C. elegans and determined the molecular mechanisms of how AD proteins affect aging, metabolism, and learning. He did his post-doctoral training with Keith Blackwell at Harvard Medical School discovering how insulin/IGF-1 signaling prolongs extracellular matrix maintenance (Ewald et al., Nature 2015). After a short junior faculty position at the Joslin Diabetes Center and as an Instructor in Medicine at Harvard Medical School he returned to Switzerland to join the Institute for Translational Medicine (ITM) as an assistant professor at ETH Zurich focusing his research on the role of the extracellular matrix during aging (www.ewaldlab.com). Dr Ewald is the founder and currently the president of the Swiss Society for Aging Research (www.ssfar.ch).

Richard Faragher is Professor of Biological Gerontology at the University of Brighton and is past Chair of the British Society for Research on Ageing, the International Association of Biomedical Gerontology and the American Aging Association. He read Biochemistry at Imperial College, London and undertook doctoral studies on human premature ageing at the University of Sussex. His primary research interest is the relationship between cellular senescence and organismal ageing.   He has published widely on the phenotype of senescent cells and on compounds that reverse the process.

He holds the Royal Pharmaceutical Society Conference Science Medal for his work on the mechanisms of Werner’s syndrome, the Help the Aged ‘Living Legend’ award for his championship of older people, the Paul F Glenn Award for research into the mechanisms of ageing and the British Society for Research on Ageing’s highest honour, the Lord Cohen of Birkenhead Medal. He is a Fellow of the American Aging Association and serves on the Editorial Boards of Advances in Biogerontology, Mechanisms of Aging and Development, Biogerontology and Advances in Biogerontology.

Professor Faragher has served as a member of the Research Advisory Council of the Charity Research into Ageing and on strategy and funding panels for the BBSRC, the US National Institutes on Ageing and the European Union. From 2005-2008 he was Co-director of the BBSRC-EPSRC SPARC programme, a research network designed to build national capacity to conduct inter-disciplinary ageing research. He is currently a Director of the American Federation for Aging Research, serves on the Scientific Advisory Board of the Longevity Vision Fund and co-directs the Building Links in Ageing Science and Translation (BLAST) research network.

Ph.D. from the University of Amsterdam. Co-founder of Gero, a data-driven longevity biotech company, that develops new drugs against aging and other complex diseases using AI-platform. An author of 75+ published papers in multiple domain areas, including publications in Science and Nature Communications.

Dr. Luigi Ferrucci is a geriatrician and an epidemiologist who conducts research on the causal pathways leading to progressive physical and cognitive decline in older persons. He has made major contributions in the design of many epidemiological studies conducted in the U.S. and in Europe. Dr. Ferrucci received a Medical Degree and Board Certification in 1980, Board Certification in Geriatrics in 1982 and Ph.D. in Biology and Pathophysiology of Aging in 1998 at the University of Florence, Italy. Between 1985 and 2002 he was Chief of Geriatric Rehabilitation at the Department of Geriatric Medicine and Director of the Laboratory of Clinical Epidemiology at the Italian National Institute of Aging. In September 2002, he became the Chief of the Longitudinal Studies Section at NIA. From 2002 to 2014 he was the Director of the Baltimore Longitudinal Study on Aging. Dr. Ferrucci is currently the Scientific Director of NIA, since May 2011.

The Evandro F. Fang group are investigating the molecular mechanisms of human aging, and age-predisposed neurodegeneration, especially Alzheimer's disease (AD). After finished his Ph.D. training in Biochemistry with Chair Professor Tzi Bun Ng at The Chinese University of Hong Kong in 2012, he started a 5-year postdoctoral fellowship at the National Institute on Aging USA with Professor Vilhelm Bohr on DNA repair and mitophagy in accelerated ageing, and with Professor Mark Mattson on strategies to improve neuronal resilience. In September 2017, he established his independent laboratory at The University of Oslo, Norway (https://evandrofanglab.com/). The Fang laboratory is focusing on the molecular mechanisms of how cells clear their damaged and aged mitochondria, a process termed "mitophagy", as well as the roles of the NAD+-mitophagy axis in healthy ageing and AD inhibition. NAD+ is a fundamental molecule in life and health and decreases in ageing (both biological and pathological) and AD. He is fascinated with and actively engaged in moving his laboratory findings to translational applications, as involved in 5+ NAD+-based clinical trials, with the overarching goal to establish novel and safe biological approaches to promote longer and healthier human lives.

He has published over 70 papers in international peer-reviewed journals including papers in Cell, Cell Metabolism, Nature Reviews MCB, and Nature Neuroscience. He has received several awards including The NIH Fellows Award for Research Excellence 2014, 2015, an awardee of the Butler-Williams Scholar on Aging 2016 (USA), a FRIMEDBIO Young Research Talent 2017(Norway), a finalist of the 2017 ERC Starting grant, an awardee of the Norwegian Cancer Society Pink Ribbon 2020 grant, and DKNVS 'scientific award to young scientist in the natural sciences for 2020 (DKNVS' vitenskapelige pris til yngre forskere innen naturvitenskap for 2020) by The Royal Norwegian Society of Sciences and Letters.

He is the founding (co)coordinator of the Norwegian Centre on Healthy Ageing network (NO-Age, www.noage100.com), the Norwegian National anti-Alzheimer's disease Network (NO-AD, www.noad100.com), and the Hong Kong-Nordic Research Network.

Toren Finkel received his undergraduate degree in Physics and his MD and PhD degree from Harvard Medical School. Following a residency in Internal Medicine at the Massachusetts General Hospital, he completed a fellowship in Cardiology at Johns Hopkins Medical School. In 1992, after completing his clinical training, he came to the NIH as an Investigator within the Intramural Research Program of the National Heart, Lung and Blood Institute (NHLBI). Over the next 25 years at the NIH, he held various positions including Chief of the Cardiology Branch and Chief of the Center for Molecular Medicine within the NHLBI. He is a member of the American Society for Clinical Investigation (ASCI) and the Association of American Physicians (AAP). He has also been inducted as a Fellow of the American Association for the Advancement of Science (AAAS) and is an elected member of the National Academy of Medicine. He serves on numerous editorial boards including currently serving on the Board of Reviewing Editors for Science. As of Sept 1^st 2017, Dr. Finkel assumed the role of the Director of the Aging Institute, and the G. Nicholas Beckwith III and Dorothy B. Beckwith Endowed Chair of Translational Medicine at the University of Pittsburgh/UPMC. Over the last three decades, his laboratory has made significant contributions in our understanding of the role of reactive oxygen species and mitochondrial function in aging and age-related diseases. He is also the co-founder of Generian Pharmaceuticals and Coloma Therapeutics, and with his colleagues, he has co-developed several small molecules which are anticipated to be in Phase I testing within 12 months and may be of potential benefit for a range of age-related disorders.

Kristen Fortney is the co-founder and CEO of BioAge, a clinical-stage biotechnology
company developing a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging. The company uses its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records tracking individuals over the lifespan, to map out the key molecular pathways that impact healthy human aging. By targeting these pathways with a large and mechanistically diverse portfolio of drugs, BioAge will unlock opportunities to treat or even prevent diseases of aging in entirely new ways.
Kristen's scientific background is in aging biology and bioinformatics. She received her PhD in Medical Biophysics from the University of Toronto, followed by postdoctoral training at Stanford University where she was a fellow of the Ellison Medical Foundation / American Federation for Aging Research.

Vadim Gladyshev is a Professor of Medicine at Harvard Medical School, Director of the Center for Redox Medicine at Brigham and Women's Hospital, and Associate Member of the Broad Institute. Dr. Gladyshev's lab focuses on studying aging, rejuvenation and lifespan control using a combination of experimental and computational approaches. He has published more than 400 articles. Dr. Gladyshev is the recipient of NIH Pioneer, Transformative and Eureka awards and is an elected member of the National Academy of Sciences, USA.

Vera Gorbunova is an endowed Professor of Biology at the University of Rochester and a co-director of the Rochester Aging Research Center. Her research is focused on understanding the mechanisms of longevity and genome stability and on the studies of exceptionally long-lived mammals. Dr. Gorbunova earned her B.Sc. degrees at Saint Petersburg State University, Russia and her Ph.D. at the Weizmann Institute of Science, Israel. Dr. Gorbunova pioneered comparative biology approach to study aging. She also investigates the role of genomic instability and transposable elements in aging and disease. Recently she demonstrated that LINE1 elements trigger innate immune response that drives age-related sterile inflammation. She has more than 100 publications including publications in high profile journals such as Nature, Science and Cell. Her work received awards of from the Ellison Medical Foundation, the Glenn Foundation, American Federation for Aging Research, and from the National Institutes of Health. Her work was awarded the Cozzarelli Prize from PNAS, prize for research on aging from ADPS/Alianz, France, Prince Hitachi Prize in Comparative Oncology, Japan, and Davey prize from Wilmot Cancer Center.

Dr. Groth is Professor and Research Director of the Protein Memory Program at the Novo Nordisk Foundation Center for Protein Research (CPR) at Faculty of Health and Medical Sciences, University of Copenhagen. She received her PhD from University of Copenhagen in 2004 and did her post-doctoral training at Institut Curie in epigenetics.
Her research focus is to elucidate how chromatin organization and function is propagated during mitotic cell division to maintain genome and epigenome stability. The goal is to understand how mechanisms that underpin epigenetic cell memory impact on cell fate decision in development, aging and disease. Her group has developed an array of tailored genomics and proteomics technologies, which has transformed the view of chromatin replication and its implication for epigenome and genome maintenance. Among other achievements, her group demonstrated how cells identify sister chromatids to direct error-free repair of DNA lesions and they identified mechanisms underlying epigenetic inheritance of histone modifications. In 2018, Anja Groth co-founded Ankrin Therapeutics, a spin-out company that targets epigenetic mechanisms for cancer therapy.

Eva Hoffmann is professor of molecular genetics and Head of Department of the Department of Cellular and Molecular Medicine at the Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.

She obtained her PhD in Biochemistry for University of Oxford and held research fellowships from EMBO as well as the Royal Society and Medical Research Council in the UK from 2005-2015 as principle investigator at the MRC Genome Damage and Stability Centre. In 2016, she relocated to the Danish National Research Foundation (DNRF) Center for Chromosome Stability at the University of Copenhagen Medical School. She is currently a Novo Nordisk Foundation Young Investigator and European Research Council award holder.

Her research focusses on exploring genetic regulation of reproductive traits and the DNA damage response in governing genome instability in human gametes and embryos. Prof. Hoffmann is an elected member of the European Molecular Biology Organization (EMBO), serves on the Executive Board and as Scientific Coordinator of ReproUnion. She is also a member of the Danish Medical Research Council and National Committee for Research Infrastructure.

Dr.Christine Huang Yuan is the Technology Transfer Director of Hong Kong Quantum AI Lab and was selected as one of Forbes China 2020 “30 Under 30 (Healthcare and Science)”. She is also an Honorary Senior Research Associate at the University of Hong Kong. Christine has vast experience in the biotechnology field,  and shares her professional insights as a biomedicine investment consultant for China Internet Investment Finance Holding Limited (stock code: 0810.HK) and as a consultant to Insilico Medicine. She is also a member of the Advisory Board of Wing Wah Charity Foundation Hong Kong, and a Fellow of the Royal Society of Medicine(UK). Christine is a translational medicine expert especially in the fields of AI-driven medicine, neurodegenerative disease and longevity medicine.

Lisa, an accomplished non-profit executive with more than 25 years of experience in administration, fundraising, donor engagement, strategy and finance, leads global operations for the LSF. Her career spans diverse sectors, including education, healthcare, human services and science. Lisa's previous roles include Vice President for Institutional Advancement at the RMSC (Rochester Museum & Science Center), where she advanced the organisation's mission through strategic planning, leadership and the formation and execution of a comprehensive fundraising strategy. Prior to her time at the RMSC, she served as the Director of Donor Relations and Stewardship at RIT (Rochester Institute of Technology), leading key initiatives to strengthen donor relationships through improved engagement, recognition, and stewardship programs. She was also Executive Director of United Way of Orleans, overseeing all aspects of the organisation and its 25 programs.
Lisa holds a Bachelor's degree in Communications with a minor in Political Science from St. John Fisher University.

Dr. Brian Kennedy is internationally recognized for his research in the basic biology of aging and as a visionary committed to translating research discoveries into new ways of detecting, delaying, preventing and treating human aging and associated diseases. He is a Distinguished Professor in Biochemistry and Physiology at the Yong Loo Lin School of Medicine at National University Singapore and serves as Director of (1) the Centre for Healthy Longevity at the National University Health System, (2) the Healthy Longevity Translational Research Programme, and (3) the Asian Centre for Reproductive Longevity and Equality. Collectively, NUS aging research seeks to demonstrate that longevity interventions can be successfully employed in humans to extend healthspan, the disease-free and highly functional period of life.

From 2010 to 2016, Dr. Kennedy was the President and CEO of the Buck Institute for Research on Aging and he maintained a professorship there through 2020. Dr. Kennedy has an adjunct appointments at the Department of Biochemistry at the University of Washington, where he was a faculty member from 2001 to 2010. In addition, Dr. Kennedy is also actively involved with a number of Biotechnology companies. In addition, Dr. Kennedy serves as a Co-Editor-In-Chief at Aging Cell. Finally, Dr. Kennedy has a track record of interaction in China, where he was a Visiting Professor at the Aging Research Institute at Guangdong Medical College from 2009 to 2014. His Ph.D. was performed in the laboratory of Leonard Guarente at M.I.T., where he published the first paper linking Sirtuins to aging.

The major research focus of James L. Kirkland, M.D., Ph.D., is the impact of cellular aging (senescence) on age-related dysfunction and chronic diseases, especially developing methods for removing these cells and alleviating their effects. Senescent cells accumulate with aging and in such diseases as dementias, atherosclerosis, cancers, diabetes and arthritis.
The goal of Dr. Kirkland's current work is to develop methods to remove these cells to delay, prevent, alleviate or partially reverse age-related chronic diseases as a group and extend health span, the period of life free of disability, pain, dependence and chronic disease.

As a longevity enthusiast and lifelong tech geek, Dr. Rob Konrad believes that the more you know about your body, the more you can improve your health and wellbeing – you can only manage what you can measure! As CEO and Co-Founder of Biolytica, a Swiss health data enterprise, together with his team of physicians, genetics experts, bioinformaticians, health coaches, dieticians, chronobiology experts, data specialists and many others, he has created the first truly comprehensive health management platform, Biolytica NEXUS, that integrates genetics, epigenetics, proteomics, labs and biomarkers, wearable device data and much more to create truly personalized health optimization programs.

Folkert Kuipers PhD (1957) is Professor of Pediatrics and Scientific Director of the European Research Institute for the Biology of Ageing (ERIBA)/head of the Department of the Biology of Ageing at the University Medical Center Groningen (UMCG) since 2022. He studied biology/biochemistry at the University of Groningen (UoG) and received his PhD degree in Medical Sciences at UoG in 1987. After a research fellowship from the Royal Netherlands Academy for Arts and Sciences (5y) and an Established Investigatorship from the Netherlands Heart Foundation (5y), he was appointed as Professor of Pediatrics in 2000 and was Head of the Laboratory of Pediatrics at UMCG from 2000-2008 and 2016-2022. His research program deals with molecular (dys) regulation of cholesterol, bile acid and lipid metabolism and transport in liver and intestine in inherited and age-related metabolic diseases, including roles of the gut microbiome. He is (co-)author of >350 peer-reviewed publications and has supervised >40 PhD theses. From 2008-2016 he served as Dean of the Faculty of Medical Sciences/UMCG and was involved in initiation and implementation of the Healthy Ageing program at UMCG, with population cohort Lifelines and ERIBA as scientific flagship projects. He holds the Noaber Foundation Healthy Life named professorship. Currently, he serves in the Scientific Advisory Board of the Netherlands Heart Foundation and is member of the External Advisory Boards of the Robert and Arlene Kogod Center for Aging Research, Mayo Clinic, Rochester, MN, USA and the Multidisciplinary Institute for Ageing (MIA), University of Coimbra, Coimbra, Portugal.

Morten Scheibye-Knudsen is Associate Professor and group leader at the Center for Healthy Aging, University of Copenhagen, Denmark. Besides his research activity, he has been committed to educational programs and his online companies Mitodb.com and Forsøgsperson.dk. The latter has grown to become the largest single provider of study participants in Denmark. Morten Scheibye-Knudsen earned his MD in 2007 and his PhD in 2016 from the University of Copenhagen. After graduation, he worked as physician at Slagelse Hospital and at Nuuk Medical Clinic in Greenland. In 2008, he became a Postdoctoral Fellow at the National Institute on Aging at the NIH in Baltimore, Maryland. His work focused on the cross-talk between DNA repair and mitochondrial function in aging and has been honored by a number of competitive awards. In 2015 he was recruited to start his own research group at the University of Copenhagen, where his research group aims to understand the cellular and organismal consequences of DNA damage in the context of aging. With the ultimate goal to modulate and perhaps treat aging and age-related diseases, allowing everyone to live healthier and longer lives.

Wenbin Li, MD, PhD, chief Physician, professor, director of cancer center and the Neuro-oncology department, Beijing Tiantan Hospital, Capital Medical University, vice president of the National Health Care Big Data (Capital Medical University) Research Institute, dean of the Department of Oncology in Capital Medical University, Chairman-designate of the Neuro-oncological Drug Clinical Research Committee, China Pharmaceutical Innovation and Research Development Association, deputy Chairman of the Gliomal Committee, Chinese Anti-Cancer Association, board member of “Signal Transduction and Targeted Therapy” and “Cancer Biology & Medical”, chief Editor of “Neuro-Tumor Channel of Medical Reference”. He is one of Leading Experts of Chinese and Western Medicine in Beijing, honorary Research Fellow of the University of South Florida. He is an expert in chemotherapy and clinical trials for brain tumors, was PI for two phase I clinical trials of China key innovative drugs during the 13th Five-Year Plan period. He is also the general coordinator in China for GBM AGILE international multi-center clinical trials.

Dr. Valter Longo is the Edna M. Jones Professor of Gerontology and Biological Sciences and Director of the Longevity Institute at the University of Southern California –Leonard Davis School of Gerontology, Los Angeles, one of the leading centers for research on aging and age-related disease. Dr. Longo is also the Director of the Longevity and Cancer Program at the IFOM Institute of Molecular Oncology in Milan, Italy.

Dr. Longo studied biochemistry as an undergraduate at the University of North Texas, and received his PhD in Biochemistry from UCLA, where he worked under calorie restriction guru Roy Walford, MD. He completed his postdoctoral training in neurobiology with longevity pioneer, Caleb Finch, PhD. He also received extensive training in immunology, endocrinology, microbiology, genetics, molecular biology, and pathology.

His studies focus on the fundamental mechanisms of aging in simple organisms and mice and on how these mechanisms can be translated to humans. The Longo laboratory has identified some of the key genetic pathways that regulate aging in simple organisms and has demonstrated that the inactivation of such pathways can reduce the incidence or progression of multiple diseases in mice and humans. His laboratory has also developed both dietary and genetic interventions that protect normal cells while sensitizing cancer cells to chemotherapy— interventions now being tested in many US and European hospitals.

Professor Maier, a Fellow of the Royal Australasian College of Physicians (FRACP), graduated in Medicine (MD) 2003 from the University of Lübeck (Germany), was registered 2009 in The Netherlands as Specialist in Internal Medicine-Geriatrics and was appointed Full Professor of Gerontology at Vrije Universiteit Amsterdam (The Netherlands) in 2013. From 2016 to early 2021 Professor Maier has served as Divisional Director of Medicine and Community Care at the Royal Melbourne Hospital, Australia, and as Professor of Medicine and Aged Care at the University of Melbourne, Australia. She continues her career at the National University of Singapore as Co-Director of the Centre for Healthy Longevity. Professor Maier's research focuses on unraveling the mechanisms of ageing and age-related diseases. During the last 10 years she has conducted multiple international observational studies and intervention trials and has published more than 300 peer-reviewed articles, achieving an H index of 54, spearheading the significant contributions of her highly acclaimed innovative, global, multidisciplinary @Age research group. She is a frequent guest on radio and television programs to disseminate aging research and an invited member of several international academic and health policy committees. She currently is the President of The Australian and New Zealand Society for Sarcopenia and Frailty Research.

Dr. Julia von Maltzahn has been a Group leader at the Leibniz Institute on Aging, Fritz-Lipmann Institute (FLI), Jena, Germany since October 2013 after working as a Postdoctoral fellow in the laboratory of Prof. Dr. Michael Rudnicki at the Sprott Center for Stem Cell Research in Ottawa, Canada. Her research focuses on intrinsic and extrinsic changes in muscle stem cells which occur during aging and how this affects regeneration of skeletal muscle.

Joan Mannick is the Chief Executive Officer and Co-Founder of Tornado Therapeutics which is developing next generation mTOR inhibitors to treat aging-related diseases. Prior to joining Tornado, Joan Mannick was Head of Research and Development at Life Biosciences and Chief Medical Officer of resTORbio which was a spinout of a clinical program targeting aging biology that she led as an Executive Director at the New Indications Discovery Unit of the Novartis Institutes of Biomedical Research. Prior to Novartis, Dr. Mannick was a Medical Director at Genzyme working in multiple therapeutic areas and was faculty member at Harvard Medical School and University of Massachusetts Medical School. Dr. Mannick received her A.B. from Harvard College and her M.D. from Harvard Medical School. She completed her residency in Internal Medicine and an Infectious Disease fellowship at Harvard Medical School.

Robin Mansukhani is the CEO and Co-Founder of Deciduous Therapeutics, a venture-backed start-up developing novel immunotherapies to treat age related diseases. He also been an advisor to several early stage biotech companies in the Aging and CNS space including Therini Bio, Reservoir Neurosciences, and Lime Therapeutics. Previously, Robin co-founded and served as President and CEO of Alzeca Biosciences, a diagnostic imaging company for CNS disorders, which is currently in clinical trials and supported by venture investors, the Alzheimer's Drug Discovery Foundation, and an NIH Direct to Phase 2 Grant. Robin has been an invited keynote speaker both domestically and abroad, including TEDx. Previously, Mr. Mansukhani worked in early stage venture capital at The Maple Fund and investment banking at Axiom Capital. He has also co-founded BlueStamp Engineering, an intensive, project-based engineering program for high school students. Robin previously served a term in AmeriCorps where he led health and literacy programs. Mr. Mansukhani holds a B.S. in Biochemistry from Case Western Reserve University.

Jerry McLaughlin is Chief Executive Officer and board member of Life Biosciences, Inc. He has over 30 years of experience in the biopharmaceutical industry and has been involved in the discovery, clinical development, and global commercialization of more than a dozen FDA-approved drugs with multiple successful exits. Most recently, Jerry was President and CEO for Neos Therapeutics, Inc., a commercial stage pharmaceutical company. Before that, he served as President and CEO of AgeneBio, Inc., a clinical-stage private biopharma company developing therapies for neurological and psychiatric diseases. Earlier, he held the role of Senior Vice President & Chief Commercial Officer at NuPathe Inc., acquired by Teva Pharmaceuticals in 2014. Jerry began his career at Merck and was extensively involved in multiple blockbuster product launches. He holds a BA in economics from Dickinson College and an MBA from the Villanova School of Business.

Prof. Alexey Moskalev is a Corresponding member of Russian Academy of Sciences, Doctor of Biology, the Head of the Laboratory of Geroprotective and Radioprotective Technologies in the Institute of Biology of Komi Scientific Centre of the Ural Branch of the Russian Academy of Sciences, the Head of the Department of Ecology of the Syktyvkar State University named after Pitirim Sorokin, the Head of the Laboratory of Genetics of Aging and Longevity in the Moscow Institute of Physics and Technology

Pura Muñoz-Cánoves studied Pharmacology at the University of Valencia. She obtained her PhD in Biology at the Madrid Autonomous University for work carried out at The Scripps Research Institute, and did postdoctoral work at the University of California-San Diego and The Scripps Research Institute, and in 1995 she joined the Cancer Research Institute (now IdiBell) in Barcelona as a postdoc, becoming an independent group leader in 1997. In 2002 her group moved to the Center for Genomic Regulation (CRG) in Barcelona, and she became a senior group leader in 2007 in that Institution. Since 2008, she was an ICREA Professor and Cell Biology Professor in the Department of Experimental and Health Sciences at the UPF in Barcelona, and later she hold a senior group leader position at Centro Nacional de Investigaciones Cardiovasculares (CNIC) in Madrid. She is a member of EMBO and Academia Europaea. At present, she is a principal investigator in Altos Labs, San Diego Institute of Science. The focus of her laboratory is understanding tissue regeneration in aging and disease.

Her research career has been dedicated to investigating the impact of DNA damage on the structure of DNA, cell function and organism health. The DNA in each of our cells is damaged thousands of times per day by exposure to environmental factors, dietary components, chemotherapeutic agents and even endogenous by-products of normal metabolism. Studying patients with rare diseases caused by inherited defects in DNA repair provides important insight into the consequences of DNA damage. These patients have a dramatically increased risk of cancer and age prematurely. We engineered mouse models of these genome instability syndromes as a sensitive tool to test hypotheses about how DNA damage promotes cancer and aging.

Bente Klarlund Pedersen, MD MDSc, is Professor of Integrative Medicine, a specialist in infectious diseases and internal medicine and chief physician at Copenhagen University Hospital – Rigshospitalet, Denmark. She is the Director of Centre for Physical Activity Research (CFAS), which count 27 senior researchers/postdocs, 14 PhD students, 16 other academic and technical personnel, 11 pre-graduate students and an administration of 4 persons (http://aktivsundhed.dk).

The research group has identified skeletal muscle as an endocrine organ that produces and releases so-called "myokines". The identification of myokines provides a conceptual basis for understanding how muscles communicate with other organs. Through translational research, the aim is to develop targeted exercise training regimes for specific disease groups by applying a translational strategy: "from bedside to bench and back".

BKP has had many positions of trust and is a member of the Royal Danish Academy of Sciences and Letters. BKP has more than 700 scientific publications, > 58.000 citations and her "H"-index is 121 (Web of Science).
BKP has written several popular books about exercise and health. She has contributed to hundreds of articles in the public press. BKP writes weekly columns on health and serves as letters editor for Politiken.
In addition, her research has been featured internationally to a broad audience on several occasions.
She has received several prizes, including the "Rosenkjærpris".

Interests include genetic (CRISPR and mRNA) technologies to treat aging, computational approaches to monitor aging, and small molecule drug mechanisms of action.

Thomas A. Rando is an American neurologist. Rando is best known for his research on basic mechanisms of stem cell biology and the biology of aging, as well as for contributions to the study of the muscular dystrophies and the emerging field of regenerative rehabilitation. He is a Professor of Neurology and Neurological Sciences at Stanford University School of Medicine, where he is founding director of the Glenn Center for the Biology of Aging. Rando is also Chief of Neurology at the VA Palo Alto Health Care System.

Michael Ringel is a Managing Director and Senior Partner at BCG, and BCG's Global Topic Leader for Growth and Innovation. He is a frequent author and speaker on R&D and innovation topics. His TED talk on innovation can be viewed at TED.com. He is also Strategic Advisor to Life Biosciences, a company targeting aging biology to address multiple diseases.

Prior to BCG, Michael worked in academia, pursuing research in theoretical population dynamics and conducting field experiments in the Amazon basin near Manaus, Brazil. Michael holds a B.A. summa cum laude in biology from Princeton, a Ph.D. in biology from Imperial College, and a J.D. cum laude from Harvard Law School. He Chairs the Board of the ATOM Consortium, a public-private partnership with a mission of transforming drug development using advanced analytics.

Dr. Robbins received his B.A. from Haverford College, his Ph.D. from the University of California at Berkeley and then worked as a post-doctoral fellow in the laboratory of Dr. Richard Mulligan at the Whitehead Institute at MIT. He was an Assistant, Associate and then full Professor of Microbiology and Molecular Genetics at the University of Pittsburgh School of Medicine as well as Director of Basic Research for the Molecular Medicine Institute and Co-Director of the Paul Wellstone Cooperative Muscular Research Center. He then was a Professor of Molecular Medicine at Scripps Research in Jupiter, Florida and Director of the Center on Aging. He currently is a Professor of Biochemistry, Molecular Biology and Biophysics and Associate Director of the Institute on the Biology of Aging and Metabolism at the University of Minnesota. His current research is focused on developing therapeutic approaches to extend healthspan. He has co-authored more than 355 peer-reviewed manuscripts and 205 book chapters and reviews with an H-index of 133, i10-index of 483 and ~68,000 citations and has edited four books.

Dr. Rosenzweig-Lipson holds significant expertise in screening strategies, in vivo models, translation, and clinical development strategy with more than three decades of experience developing compounds for psychiatric and neurologic indications in the pharmaceutical industry and in biotech. Her career in big pharma includes American Cyanamid, American Home Products, Wyeth, and Pfizer. Most recently, as head of R&D, Dr. Rosenzweig-Lipson led the clinical development of AgeneBio’s lead asset through Phase 2B trials as well as the company’s preclinical development programs. Dr. Rosenzweig-Lipson earned her BA in the biological basis of behavior from the University of Pennsylvania and her PhD in behavioral neuroscience from Harvard University.

Since 2013, Björn Schumacher is full professor and director of the Institute
for Genome Stability in Ageing and Diseases (IGSAD) at the CECAD
Research Centre of the University of Cologne. He received his PhD at the
Max Planck Institute for Biochemistry in Munich and conducted his
postdoctoral research as EMBO and Marie Curie fellow at the Erasmus
Medical Centre in Rotterdam. Professor Schumacher is President of the
German Society for DNA Repair (DGDR), co-Director of the Minerva Center
of the Biological Mechanisms of Healthy Ageing at Bar-Ilan University (IL),
and between 2014 and 2020 served as President of the German Society
for Ageing Research (DGfA). He was awarded with the Eva Luise Köhler
Research Prize, the Innovation Prize of the State of North Rhine-
Westphalia, the European Research Council (ERC) starting grant,
coordinated the FP7 Marie Curie initial training network on chronic DNA
damage in ageing (CodeAge) and serves on several editorial boards. His
research interest focuses on the molecular mechanisms through which
DNA damage contributes to cancer development and ageing-associated
diseases. Employing the C. elegans system and mammalian disease
models, his group uncovered cell-autonomous and systemic responses
through which the organism adapts to accumulating DNA damage with
ageing. Through the understanding of the basic mechanisms of genome
instability-driven ageing, Schumacher aims to contribute to the
development of future strategies to prevent ageing-associated diseases.

Dr. Vittorio Sebastiano is an Associate Professor in the Department of Obstetrics and Gynecology at Stanford School of Medicine. His lab has established a new technology named ERA^TM, which repurposes the conceptual idea of reprogramming, with the goal to promote epigenetic rejuvenation of adult cells leaving their identity untouched. This new technology was patented and is being implemented by Turn Biotechnologies, of which Dr. Sebastiano is co-founder, Head of Research and Chair of the Scientific Advisory Board.

In 2009, Dr. Sebastiano completed a postdoctoral fellowship at the laboratory of Dr. Marius Wernig at Stanford University, where he implemented the newly discovered iPSC technology and was among the first to demonstrate that iPSCs can be efficiently derived, genetically modified, and implemented for cell therapy in genetic diseases (Sebastiano et al., 2014, Science Translational Medicine).

Dr. Sebastiano completed his undergraduate and graduate studies at the University of Pavia, Italy, where he studied murine germ cells and preimplantation development and where he pioneered cellular reprogramming by Somatic Cell Nuclear Transfer. He joined the Max Planck Institute for Molecular Biomedicine as a postdoctoral fellow under the mentorship of Dr. Hans Robert Schöler, where he continued his research on cellular reprograming, germ cells biology, and embryonic development.

John Sedivy is the Hermon C. Bumpus Professor of Biology, and Director of the Center for the Biology of Aging at Brown University. He has a long-standing interest in mammalian genetics, signalling and cell cycle control. His achievements include developing one of the first methods for targeted homologous recombination, generating the first viable knockout of c-Myc in rat fibroblast cells, achieving the first homozygous gene knockout (CDKN1A) in primary human cells, which led to the discovery that p21 is a key regulator of entry into cellular senescence, and showing that cellular senescence is regulated in parallel by the p53-p21 and p16-pRb pathways. In 2004 his lab developed an assay for dysfunctional telomeres as a single-cell biomarker of senescence and delineated the signalling pathway between dysfunctional telomeres and the cell cycle. This led to the first in vivo quantification of cellular senescence in ageing primates. His other discoveries include the finding that retrotransposons are activated with age in somatic cells, and that retrotransposon LINE-1 activation triggers host interferon and innate immune responses. Currently, he works on exploring the involvement of LINE-1 in neurodegenerative diseases and the lifecycles of LINE-1 elements in ageing and senescent cells. John's research has been funded by the NIH for over 30 years, including a MERIT Award from the NIA. He has been a founding member and chair of the NIH CMAD study section, Editor-in-Chief of the journal Aging Cell, chair of the 2015 Gordon Research Conference on the Biology of Aging and is the author of numerous articles. He has consulted widely for the biotech industry and fulfilled major leadership roles at Brown University, including chairing his department and founding an academic centre for Genomics and Proteomics and the Brown Center on the Biology of Aging.

Assistant Professor Tsai received her Ph.D. in Dr. Gustavo Leone's lab at the Ohio State University (2009), where she studied the mechanisms by which mammalian E2F transcription factors control cell proliferation. She showed the functional redundancy among E2F activators during development and the specific roles of E2F family members during long-term maintenance. After her Ph.D., she did her postdoctoral training in Dr. Brian Kennedy's lab at the University of Washington and continued her research at the Buck Institute. She investigated the role of mTORC1 downstream translation effecter, 4E-BP1, in regulating metabolic homeostasis during the progression of type II diabetes and aging. Since February 2017, she started her lab as an Assistant Professor at the Department of Physiology at the National University of Singapore. Her study focuses on exploring how protein homeostasis in the regulation of muscle health. Using transgenic mouse models and primary 3D in vitro models of skeletal muscle, her lab studies the aging process at molecular levels to provide an explicit picture of muscle aging for potential therapeutic usage.

David A. Sinclair, Ph.D., A.O. is a Professor in the Department of Genetics, Blavatnik Insitute, and co-Director of the Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School. He is best known for his work on understanding why we age and how to slow its effects. He obtained his Ph.D. in Molecular Genetics at the University of New South Wales, Sydney, in 1995 and did his postdoctoral research at M.I.T. with Dr. Leonard Guarente where he co discovered a cause of aging for yeast as well as the role of Sir2 in epigenetic changes driven by genome instability and aging. In 1999 he moved to Harvard Medical School and has primarily focused on understanding why we age and the role of protective enzymes called the sirtuins, which respond to changing NAD+ levels, exercise, and caloric restriction (CR). The Sinclair lab was the first to identify a role for NAD biosynthesis in the regulation of lifespan and first showed that sirtuins are involved in CR's benefits in mammals and identified the first small molecules that activate SIRT1 (STACs). His lab is alos working on epigenetic changes as a driver of aging and the use of reprogramming factors to reset the age of cells and tissues. He is the New York Times bestselling author of Lifespan (2019), has published over 200 scientific papers, is a co-inventor on over 50 patents, and has co-founded biotechnology companies in the areas of aging, vaccines, diabetes, infectious diseases, immunity and cancer. He serves as co-chief editor of the scientific journal Aging and has received 35 honors including the Australian Medical Research Medal, the Irving Wright Award, the NIH Director's Pioneer award, TIME magazine's list of the "100 most influential people in the world" and the "Top 50 people in Healthcare". In 2018, he became an Officer of the Order of Australia (AO).

Katja Simon trained as an Immunologist at the Deutsche Rheumaforschungszentrum, Berlin and during her PhD showed that TH1 cytokines are found in excess in human rheumatoid arthritis joints. For this work, she was awarded the European League Against Rheumatism EULAR award. After postdocs at the Centre d'Immunologie Marseille Luminy and at the Weatherall Institute in Oxford, where she focused on cell death pathways in the immune system, she became a principal investigator. With her team, she pioneered the field of autophagy in the immune system. Her group discovered that autophagy, the main cellular bulk degradation pathway, promotes differentiation of healthy red blood cells and neutrophils, and maintains long-lived cells such as stem and memory T cells. She also showed that it prevents ageing of immune cells and can be used to reverse immune senescence. She has been a Wellcome investigator since 2015. In 2016 she moved to the Kennedy Institute of Rheumatology and became a full professor. In 2022 she started a new group at the MDC in Berlin with funding from the Helmholtz Society for distinguished professors. She received the 2018 Ita Askonas prize for outstanding achievements as a female European Immunology group leader.

John Speakman is a Professor at the Shenzhen Institutes of Advanced Technology in Shenzhen, China and also at the University of Aberdeen in Scotland, UK. He has been working on energy balance and obesity for more than 40 years. During that time he published over 600 scientific papers including 11 in Nature/Science, and was featured twice on the cover of Nature. He is a foreign member of the US National Academy of Sciences, an academician of the Chinese National Academy of Sciences and a Fellow of the UK Royal Society. In 2020 he was awarded the US Obesity Society TOPS award (their premier research award) and was also awarded the Osborne-Mendel prize by the American Society of Nutrition for basic research.

Yousin Suh, Ph.D., is the Charles and Marie Robertson of Reproductive Sciences in Obstetrics and Gynecology, Professor of Genetics and Development, and Director of Reproductive Aging in Obstetrics and Gynecology in the Vagelos College of Physicians and Surgeons at Columbia University. She investigates the (epi)genetic component that underlies the interface of intrinsic aging and disease. The approach she follows is based on the identification of (epi)genome sequence variants associated with age-related disease risk or its opposite, i.e., an unusual resistance to such disease. For this purpose her target populations are either cohorts of middle-aged individuals followed longitudinally for signs of all major age-related diseases, or cohorts of extremely long-lived individuals who managed to ward off such diseases. To tackle the key problem of identifying the functional impact of any observed association, she applies specific functional tests, including in silico modeling, cell culture assays and mouse models. Discoveries thus far made include novel, rare alleles associated with extreme longevity, sirtuin variants that confer risk for heart disease, functional non-coding variants in the gene desert Chr. 9p21 locus underlying multiple age-related diseases, longevity-associated miRNAs, and epigenetic signatures of cellular senescence. Her contributions in the field have been recognized by the Glenn Award for Research in Biological Mechanisms of Aging. She has organized numerous international symposiums on functional genomics of aging, is on the Editorial Boards of numerous Journals including PLoS Genetics and Aging Cell as an Associate Editor, and participates in advisory committee members for several research institutions and companies.

Emma Caroline Teeling is an Irish zoologist, geneticist and genomicist, who specialises in the phylogenetics and genomics of bats. Her work includes understanding of the bat genome and study of how insights from other mammals such as bats might contribute to better understanding and management of ageing and a number of conditions, including deafness and blindness, in humans. She is the co-founder of the Bat1K project to map the genomes of all species of bat. She is also concerned with understanding of the places of bats in the environment and how to conserve their ecosystem.
Teeling is a full professor at University College Dublin, where she has founded two scientific centres: the Laboratory of Molecular Evolution and Mammalian Phylogenetics (also known as the "BatLab"), and the Dublin part of the Centre for Irish Bat Research. Teeling is widely cited in her areas of study and is an elected member of Ireland's national academy, the Royal Irish Academy.

Prof. Tzipi Strauss specialized in Pediatrics at the Sheba Medical Center. During her internship she spent two years in the Netherlands at the Leiden University Medical Center LUMC and conducted a research in the Department of Premature Infants. Later she specialized in neonatology and premature neonatal medicine at Sheba.

In 2010 she was appointed Deputy Director of the Edmond and Lily Safra Children's Hospital and in 2012 was appointed Director of the Neonatology Department and NICU. She later received her MSc in Health care management from Harvard University.

Her main areas of research are hemostasis and coagulation in preterm infants

Mourad Topors is the Chief Scientific Officer of Repair Biotechnologies. He has deep experience in leading and managing multi-disciplinary teams in translational medical research with a strong focus in cardiovascular disease. Formerly, Dr. Topors was Principal Investigator and Faculty at Harvard Medical School and served as Team Leader of a drug development program at Pfizer’s Center for Therapeutic Innovations. He holds a PhD in Experimental Medicine from McGill University and a postdoctoral fellowship in the Department of Immunology at the University of Toronto.

Dario Riccardo Valenzano studied neuroscience at the Scuola Normale Superiore in Pisa (Italy) and did a postdoc at Stanford University. He is full professor at the Friedrich Schiller University in Jena (Germany) and Senior Group Leader at the Leibniz Institute on Aging (Fritz-Lipmann Institute), where he coordinates the research focus Microbiome and Aging.
The Valenzano research team studies the genomic basis of short/long lifespan across species and investigates the role of commensal gut microbes during aging. Their main model system is the naturally short-lived turquoise killifish (Nothobranchius furzeri), which they study in the lab as well as in their natural habitat in the African savannah.

Liesbeth Veenhoff is an associate professor at the European Research Institute for the Biology of Ageing at the University of Groningen. She received her PhD and postdoctoral training at the University of Groningen (Prof. Bert Poolman) and the Rockefeller University in New York (Prof. Michael Rout).

The lab's main research line is to understand the role of the nuclear pore complex (NPC) in ageing. The nuclear pores are the sole gateways to the interior of the nucleus and their function is essential to all eukaryotic life. The NPC's function is intimately connected to the primary hallmarks of ageing of protein homeostasis and genome stability, and several processes underlying these hallmarks are orchestrated at NPCs. Complementing these NPC-centered studies, we aim to contribute to a better understanding of the cellular ageing process in general. Here, our strategy is to 'simply' observe live ageing cells, and quantify new molecular and physicochemical aspects of ageing.

We design our research from the viewpoint that studying "biology in time" is an unbiased way to reveal fundamental knowledge; knowledge that is needed to combat age-related diseases.

Dr. Verdin is the president and chief executive officer of the Buck Institute for Research on Aging. A native of Belgium, Dr. Verdin received his Doctorate of Medicine (MD) from the University of Liege and completed additional clinical and research training at Harvard Medical School. He has held faculty positions at the University of Brussels, the National Institutes of Health (NIH), and the Picower Institute for Medical Research. Dr. Verdin is also a professor of medicine at University of California, San Francisco.

Dr. Verdin studies how metabolism, diet, and small molecules regulate the activity of HDACs and sirtuins, and thereby the aging process and its associated diseases, including Alzheimer's. He has published more than 210 scientific papers and holds more than 15 patents. He is a highly cited scientist (top 1 percent) and has been recognized for his research with a Glenn Award for Research in Biological Mechanisms of Aging and a senior scholarship from the Ellison Medical Foundation. He is an elected member of several scientific organizations, including the American Association for the Advancement of Science, the American Society for Clinical Investigation, and the Association of American Physicians. He also serves on the advisory council of National Institute on Drug Abuse at the National Institutes of Health.

Jan Vijg is currently the Director, Center for Single-Cell Omics, School of Public Health, Jiao Tong University School of Medicine, Shanghai. Prior to this he served as an Adjunct Professor, Department of New Biology, Daegu Gyeongbuk Institute of Science and Technology, Daegu, Republic of Korea. His research has long been focused on genomic instability and its relationship with aging, mainly using transgenic mouse and Drosophila models harboring mutational reporter genes. Dr, Vijg is a graduate of the State University of Leiden, The Netherlands with a BA in Biology, MSc in Molecular Biology and a PhD in Molecular Biology.

Ken Walsh is the Lockhart B. McGuire Professor and Director of the Hematovascular Biology Center at the University of Virginia. The Walsh Lab broadly examines the molecular events that control cellular growth, differentiation and death. Their newest studies investigate "clonal hematopoiesis" and how this condition contributes to age-associated diseases. Although primarily focused on cardiovascular health, studies of clonal hematopoiesis have major implications for seemingly unrelated diseases, such as diabetes and cancer, and it may contribute to biological aging per se. Dr. Walsh obtained his PhD in Biochemistry from the University of California, Berkeley and performed post-doctoral studies at the Massachusetts Institute of Technology. Dr. Walsh has published more than 400 scientific articles and he is the recipient of multiple research grants from the National Institutes of Health, including a prior MERIT Award, the National Aeronautics and Space Administration and the Department of Defense.

Sara Wickström received her MD in 2001 and PhD in 2004 from the University
of Helsinki, Finland. After postdoctoral training at the Max Planck Institute (MPI)
for Biochemistry she became Group Leader at the MPI for Biology of Ageing in 2010. In 2018 her laboratory moved to the University of Helsinki where she was professor of Cell and Developmental Biology. In 2022 Wickström was appointed as Director
of the MPI for Molecular Biomedicine in Münster.
Research in the Wickström lab aims to understand how mammalian epithelial tissues are generated and maintained, and in particular how mechanical forces and cellular interactions integrate single cell behaviors to pattern these structurally extremely robust yet dynamic tissues.

Tony Wyss-Coray is the D. H. Chen Distinguished Professor of Neurology and Neurological Sciences at Stanford University, Associate Director of the Paul F. Glenn Center for the Biology of Aging, and the Director of the Stanford Alzheimer's Disease Research Center Biomarker Core. His lab studies brain aging and neurodegeneration with a focus on age-related cognitive decline and Alzheimer's disease. The Wyss-Coray research team is following up on earlier discoveries which showed circulatory blood factors can modulate brain structure and function and factors from young organisms can rejuvenate old brains. These findings were voted 2nd place Breakthrough of the Year in 2014 by Science Magazine and presented in talks at Global TED, the World Economic Forum, Google Zeitgeist, and Tencent's WE Summit in China. Wyss-Coray is the co-founder of Alkahest, a company developing plasma-based therapies to counter age-related diseases including Alzheimer's. Current studies in his lab focus on understanding how the immune system and the organism as a whole age and communicate with the brain. Putting humans at the center of his studies Wyss-Coray integrates genetic, cell biology, and proteomics approaches and models them in the short-lived killifish and in mice. Ultimately, he tries to understand brain aging and disease at an individual level to develop tailored diagnostic and therapeutic tools.

Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (insilico.com), a leader in next-generation artificial intelligence technologies for drug discovery and biomarker development. Under his leadership, Insilico raised over $415 million in multiple rounds from expert investors, opened R&D centers in six countries or regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions, nominated 8 preclinical candidates, and entered human clinical trials with AI-discovered novel target and AI-designed novel molecule. Since 2015 he invented critical technologies in the field of generative adversarial networks (GANs) and reinforcement learning (RL) for generation of novel molecular structures with the desired properties and generation of synthetic biological and patient data. Since 2012 he published over 160 peer-reviewed research papers and 2 books.

He founded and co-chairs the Annual Aging Research, Drug Discovery and AI Forum (9th annual in 2022), the world's largest event on aging in the pharmaceutical industry. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.

Garri Zmudze is an expert investor and advisor for deeptech companies developing life-changing solutions across biotech, medicine, longevity and more.
Garri is committed to building a world where everyone has more healthy years with their loved ones. He co-founded the Longevity Science Foundation, a global nonprofit funding early-stage research on extending the healthy human lifespan, in 2021. Garri is also a co-founder and managing partner at LongeVC, a venture capital firm investing in visionary biotech and longevity.
Outside of his work with LongeVC, Garri is a top angel investor. He has several successful exits across biotech and tech companies, including Insilico Medicine, Deep Longevity and Basepaws.
Garri is a trusted advisor for top companies across web3 and biotech: Cointelegraph, IoTEX, PsyMed Ventures, Longenesis, Insilico Medicine and the Healthy Longevity Medicine Society